Chimeracom L.L.C. has announced that the US Patent and Trademark Office issued a US patent for the invention by Chimeracom’s Chief Science Officer, Dr. Richard M. Kream, of a novel method for managing a critical problem in the design of pharmaceuticals.
As Dr. Kream explained, “the blood-brain barrier protects the brain from chemicals in the blood. This barrier must be overcome to deliver potentially important therapeutic and diagnostic agents to the brain. Our patent covers a family of new drugs for the delivery of pharmacologically active peptides into the brain.”
This patent emerged from Chimeracom’s research and development of analgesic drugs. The new US Patent is no. 7,214,657, entitled Method of Transporting a Chimeric Hybrid Molecule Across the Blood Brain Barrier.